Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules, further enhancing patient access to the medication

▤ Summary

Everest Medicines has formed a commercialization collaboration with Hainan Herui for budesonide enteric capsules in mainland China. Under the deal, Everest Medicines will handle commercialization and provide technical guidance and quality audits across manufacturing and supply. The partnership aims to improve access to the newly approved treatment for IgA nephropathy and strengthen the combined franchise with NEFECON. The announcement also highlights the large unmet need in China for IgAN therapies and Everest’s broader commercialization capabilities.

▦ Linked Companies